A treatment can improve outcomes while it is delivered even when its added benefit is uncertain after it stops. A 2008 review of cognitive and behavioral therapies for methamphetamine dependence makes that timing distinction particularly clear for contingency management.
What kind of evidence was reviewed?
Lee and Rawson examined randomized cognitive and behavioral intervention studies available at the time. The review included cognitive behavioral therapy, relapse prevention, motivational approaches and contingency management. It was a historical literature review, not a new trial and not an assessment of the complete evidence available today.
The authors emphasized that much stimulant-treatment research involved cocaine, or combined cocaine and methamphetamine samples without separate analyses. Evidence labeled “stimulant treatment” therefore did not always establish a methamphetamine-specific effect.
What did contingency management mean?
Contingency management delivered a reward when a defined behavior occurred, such as submission of a drug-negative urine specimen. Different studies used vouchers, prize drawings and different schedules or maximum reward values. Attendance incentives and abstinence incentives are not identical interventions.
The practical comparator mattered too. Adding incentives to usual care asks whether the incentives improve outcomes beyond that care. Comparing incentives against a separate counseling program asks a different question. Combining these designs into one generic “treatment versus nothing” claim would misrepresent the evidence.
What happened during treatment?
The review summarized a methamphetamine-specific trial of 113 participants comparing usual care with usual care plus contingency management over 12 weeks. The incentive group provided more methamphetamine-free urine specimens and achieved longer abstinence, but retention did not differ between groups. Improvement in one endpoint did not establish improvement in every endpoint.
Another comparison involved 16 weeks of contingency management, cognitive behavioral therapy or both in a mixed-stimulant sample. Contingency management improved retention and stimulant-use outcomes during treatment, but the drug groups were not separated. That result should not be presented as a precise estimate for methamphetamine alone.
What happened after treatment?
In several comparisons, between-group differences seen during treatment were no longer apparent at follow-up. Other studies did not provide post-treatment follow-up at all. These are different evidence states: an observed nonsignificant later comparison is not the same as an unmeasured later outcome.
Neither finding proves that participants lost all improvement. If all groups improve, the added advantage of one intervention can narrow while people retain some benefit. Conversely, a significant during-treatment effect cannot be assumed to persist indefinitely when follow-up is absent.
Why does the control condition matter?
The review described brief-intervention studies in which comparison participants received a self-help booklet based on cognitive behavioral principles. Assessment and repeated follow-up could also influence behavior. An active comparison can reduce the contrast between groups without showing that neither approach helps.
Similarly, several papers could arise from one underlying trial. Multiple publications exploring mood, use and subgroup outcomes do not become independent replications merely because they have different titles.
How should this historical review be used?
It supports a disciplined reading of treatment duration, comparator and follow-up. The review identified promising during-treatment findings and uncertainty about longevity, while also documenting null results and gaps. It does not supply a current prescribing or service guideline, an optimal incentive amount or a prediction for one person.
For research interpretation, report the behavior rewarded, the drug-specific specimen endpoint, the treatment period and the actual follow-up separately. A negative urine specimen remains an outcome measurement within the trial; it is not a general certification of functional recovery or absence of impairment at another time.
Source
Lee NK, Rawson RA. A systematic review of cognitive and/or behavioural therapies for methamphetamine dependence. Drug and Alcohol Review. 2008;27:309–317. doi:10.1080/09595230801919494. Historical review of controlled human studies.
Leave a Reply